Registration and Networking
Welcome and Opening Remarks
Talk 1: To be confirmed
Public Policy at Niti Aayog, Office of Vice Chairman, Niti Aayog, Government of India
Talk 2: The Digital Clinical Trial
Managing Director, Life Science Organization, Accenture
Case Study: To be confirmed
CMO Patient Safety, Novartis Pharma AG
Coffee and Networking Break
Talk 3: How can technology solve the problem of a lack of patients in clinical trials?
Case Study: Performing large scale patient-centric real-world evidence-based researchHealth research is going through a period of rapid change driven by increased understanding that the patient needs to be seen as more than just a source of data. Rapid digitisation is helping to increase patient engagement around their healthcare and at a higher level become partners in the drive towards improved medications, and equally important ongoing collaborators all the way from clinical trials into the real world. This session will look at:
▪ The growing importance of Real World Evidence and why this will start to become a continuum flowing from the clinical trial process
▪ The growing importance of digital approaches as a technology foundation for research with examples from recent case studies in areas such as Parkinsons.
▪ The increase in the usage of patients own devices combined with sensors to drive both an individual's understanding of their health and to capture data for use in research
Attendees will leave the session understanding:
▪ An understanding how research is starting to be built around the patient, and what this patient-
centricity means for all players.
▪ How an engaged patient will help increase the quality of clinical research
▪ Insights gained from recent pivotal large scale direct to patient research in Parkinsons patients.
Head of Insight, uMotif
Talk 4: Gathering data when human clinical trials are unethical or infeasibleClinical efficacy trials in people are not always feasible or ethical, thus hampering the development and testing of countermeasures for lethal or permanently disabling toxic agents (e.g. chemical, biological, radiological or nuclear substances). This talk will give a quick overview of how the FDA Animal Efficacy Rule overcomes this problem and examples of life-saving animal models for emerging infectious diseases such as Ebola. Case study will be presented on collaboration between academic, non-profit, public and private sector organisations to combat recent emergencies such as Ebola and Zika.
Honorary Visiting Professor, University of York; Senior Business Development Manager, Public Health England,
AI enabled BOTs for patient education & assistance
CEO, RxPrism Health Systems
Lunch and Networking Break
Talk 5: The promise of AI in clinical trialsShift towards patient engagement, has generated an unprecedented amount of clinical and commercial data. Applying advanced analytics and artificial intelligence to these data can help pharma companies generate meaningful, actionable insights. In this session, you can learn how pharma marketers and patient engagement managers can use data to engage patients in a multi-channel environment and how to support them during therapy.
Director Life Sciences - Europe, IBM
Talk 6: TBC
Health and Life Sciences Industry Solutions Executive, Microsoft
Talk 7: Building an End-To- End Strategy for Patient EngagementAnd, how new technologies are enabling continuous patient engagement through the product itself,
particularly the collection of data on how patients use drugs and devices, how new technologies are enabling continuous patient engagement through the product itself, particularly the collection of data on how patients use drugs and devices.
Coffee and networking break
Talk 8: To be confirmedIn this session we will aim to identify strategies that companies are adopting to respond to challenges facing industry in its ambition to become more patient centric such as regularity uncertainty, data safety & privacy and low health literacy etc.
Talk 9: Tackling Patient Centricity & Diversity Challenges in Clinical TrialsThere’s a lot of talk about patient centricity in the clinical trial arena these days, and for good reason—hearing the voice of patient and incorporating patient perspectives into trial design can pay huge dividends for all stakeholders involved. But what does it mean to be patient centric, practically speaking? What tactics are leading pharma companies employing to make centricity a reality in their trials?
The speaker will describe their recent patient centricity initiatives, the technologies they’ve employed, and the specific benefits their efforts have yielded for their companies and their patients. In this session, they discuss programs related to patient diversity and patient recruitment at their firms and take an industry-wide look at noteworthy innovations in patient centricity.